Novan, Inc. (NOVN): Price and Financial Metrics

Novan, Inc. (NOVN): $8.40

0.26 (+3.19%)

POWR Rating

Component Grades














  • Sentiment is the dimension where NOVN ranks best; there it ranks ahead of 64.29% of US stocks.
  • NOVN's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • NOVN ranks lowest in Momentum; there it ranks in the 5th percentile.

NOVN Stock Summary

  • With a price/sales ratio of 40.27, Novan Inc has a higher such ratio than 93.98% of stocks in our set.
  • The volatility of Novan Inc's share price is greater than that of 99.79% US stocks with at least 200 days of trading history.
  • Novan Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -38.56%, greater than the shareholder yield of only 7.42% of stocks in our set.
  • Stocks that are quantitatively similar to NOVN, based on their financial statements, market capitalization, and price volatility, are SLGL, NVEC, SNGX, IMOS, and INFI.
  • Visit NOVN's SEC page to see the company's official filings. To visit the company's web site, go to

NOVN Valuation Summary

  • NOVN's price/sales ratio is 45.6; this is 1100% higher than that of the median Healthcare stock.
  • NOVN's EV/EBIT ratio has moved up 1.6 over the prior 60 months.
  • NOVN's price/earnings ratio has moved down 0.2 over the prior 60 months.

Below are key valuation metrics over time for NOVN.

Stock Date P/S P/B P/E EV/EBIT
NOVN 2021-08-31 45.6 5.6 -6.0 -3.9
NOVN 2021-08-30 45.4 5.6 -6.0 -3.9
NOVN 2021-08-27 45.6 5.6 -6.0 -3.9
NOVN 2021-08-26 43.9 5.4 -5.8 -3.7
NOVN 2021-08-25 44.9 5.5 -5.9 -3.8
NOVN 2021-08-24 45.9 5.6 -6.0 -3.9

NOVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NOVN has a Quality Grade of D, ranking ahead of 6.52% of graded US stocks.
  • NOVN's asset turnover comes in at 0.072 -- ranking 287th of 677 Pharmaceutical Products stocks.
  • VBIV, RIOT, and ASRT are the stocks whose asset turnover ratios are most correlated with NOVN.

The table below shows NOVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 1 -8.838
2021-03-31 0.097 1 -7.579
2020-12-31 0.111 1 -7.267
2020-09-30 0.132 1 -3.706
2020-06-30 0.140 1 -2.821
2020-03-31 0.134 1 -5.195

NOVN Stock Price Chart Interactive Chart >

Price chart for NOVN

NOVN Price/Volume Stats

Current price $8.40 52-week high $25.90
Prev. close $8.14 52-week low $4.33
Day low $8.04 Volume 274,200
Day high $8.61 Avg. volume 2,100,770
50-day MA $8.72 Dividend yield N/A
200-day MA $11.49 Market Cap 158.03M

Novan, Inc. (NOVN) Company Bio

Novan, Inc. focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company was founded in 2006 and is based in Durham, North Carolina.

NOVN Latest News Stream

Event/Time News Detail
Loading, please wait...

NOVN Latest Social Stream

Loading social stream, please wait...

View Full NOVN Social Stream

Latest NOVN News From Around the Web

Below are the latest news stories about Novan Inc that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Companys expectations

Intrado Digital Media | September 23, 2021

Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

– Live fireside chat with Paula Brown Stafford, President and Chief Executive Officer of Novan on Tuesday, September 28 at 8:00 AM ET – – Live fireside chat with Paula Brown Stafford, President and Chief Executive Officer of Novan on Tuesday, September 28 at 8:00 AM ET –

Intrado Digital Media | September 20, 2021

NOVN: Syneos Selected as Commercialization Partner

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT September Update On September 9, 2021, Novan (NASDAQ:NOVN) hosted a corporate update conference call and webcast. The call was led by Novan President and CEO, Paula Brown Stafford, who reviewed recent milestones and plans over the next several years. Ms. Stafford detailed Novan’s revenue prospects in the US which are

Yahoo | September 20, 2021

Novan Announces Strategic Priorities and Outlines Key Milestones

Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum Late-stage product candidate, SB204 for the treatment of acne vulgaris, selected to advance as second lead

Novan Inc | September 9, 2021

Novan Engages Syneos Health as Commercial Solutions Provider for SB206

Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in patients with molluscum contagiosum

Intrado Digital Media | September 8, 2021

Read More 'NOVN' Stories Here

NOVN Price Returns

1-mo -12.41%
3-mo -16.50%
6-mo -48.47%
1-year 64.71%
3-year -69.89%
5-year -96.12%
YTD 3.32%
2020 -74.27%
2019 280.72%
2018 -80.33%
2017 -84.38%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9011 seconds.